PL3319995T3 - Terapia skojarzona z użyciem koniugatu przeciwciało anty-her2-lek i inhibitora bcl-2 - Google Patents
Terapia skojarzona z użyciem koniugatu przeciwciało anty-her2-lek i inhibitora bcl-2Info
- Publication number
- PL3319995T3 PL3319995T3 PL16741212T PL16741212T PL3319995T3 PL 3319995 T3 PL3319995 T3 PL 3319995T3 PL 16741212 T PL16741212 T PL 16741212T PL 16741212 T PL16741212 T PL 16741212T PL 3319995 T3 PL3319995 T3 PL 3319995T3
- Authority
- PL
- Poland
- Prior art keywords
- bcl
- inhibitor
- combination therapy
- drug conjugate
- her2 antibody
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562189610P | 2015-07-07 | 2015-07-07 | |
EP16741212.1A EP3319995B1 (en) | 2015-07-07 | 2016-07-06 | Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor |
PCT/US2016/041184 WO2017007846A1 (en) | 2015-07-07 | 2016-07-06 | Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3319995T3 true PL3319995T3 (pl) | 2019-09-30 |
Family
ID=56464320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL16741212T PL3319995T3 (pl) | 2015-07-07 | 2016-07-06 | Terapia skojarzona z użyciem koniugatu przeciwciało anty-her2-lek i inhibitora bcl-2 |
Country Status (21)
Country | Link |
---|---|
US (2) | US10898570B2 (pl) |
EP (1) | EP3319995B1 (pl) |
JP (2) | JP6910339B2 (pl) |
KR (1) | KR20180021060A (pl) |
CN (2) | CN113607945A (pl) |
AU (1) | AU2016290065B2 (pl) |
BR (1) | BR112017028012A2 (pl) |
CA (1) | CA2990465A1 (pl) |
DK (1) | DK3319995T3 (pl) |
ES (1) | ES2731377T3 (pl) |
HR (1) | HRP20191019T1 (pl) |
HU (1) | HUE044139T2 (pl) |
IL (1) | IL256451B (pl) |
LT (1) | LT3319995T (pl) |
MX (1) | MX2018000135A (pl) |
PL (1) | PL3319995T3 (pl) |
PT (1) | PT3319995T (pl) |
RS (1) | RS58823B1 (pl) |
SI (1) | SI3319995T1 (pl) |
TR (1) | TR201908138T4 (pl) |
WO (1) | WO2017007846A1 (pl) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107349426B (zh) * | 2017-07-12 | 2018-03-23 | 马骥 | 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用 |
EP3980080A1 (en) * | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | Immunomodulator antibody drug conjugates and uses thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
AU760048B2 (en) | 1998-05-06 | 2003-05-08 | Genentech Inc. | Protein purification by ion exchange chromatography |
SK17282000A3 (sk) | 1998-05-15 | 2002-04-04 | Imclone Systems Incorporated | Nerádioaktívne označený inhibítor proteínového tyrozínkynázového receptora |
EP2283867B1 (en) | 1999-06-25 | 2014-05-21 | ImmunoGen, Inc. | Methods of treatment using anti-ERBB antibody-maytansinoid conjugates |
US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
CN102698265A (zh) * | 2000-05-19 | 2012-10-03 | 杰南技术公司 | 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验 |
US7795232B1 (en) * | 2000-08-25 | 2010-09-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6790954B2 (en) | 2002-01-29 | 2004-09-14 | Immunogen, Inc. | Mutant Actinosynnema pretiosum strain with increased maytansinoid production |
US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
AU2003300414A1 (en) * | 2002-12-19 | 2004-07-14 | Genta Incorporated | Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers |
US7432088B2 (en) | 2003-05-08 | 2008-10-07 | Immunogen Inc. | Methods for the production of ansamitocins |
US7004206B2 (en) | 2004-01-29 | 2006-02-28 | Viken James P | Automatic fluid exchanger |
JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Herceptin(登録商標)補助療法 |
AU2014240234B2 (en) * | 2008-03-18 | 2016-10-06 | Genentech, Inc. | Combinations of an anti-HER2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
HUE025507T2 (en) * | 2008-03-18 | 2016-02-29 | Genentech Inc | Combinations of anti-HER2 antibody-drug conjugate and chemotherapeutic agents and methods for their use |
SG10201704742YA (en) | 2009-05-26 | 2017-07-28 | Abbvie Ireland Unlimited Co | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
ES2650674T3 (es) * | 2010-04-19 | 2018-01-19 | Biomarker Strategies, Llc. | Composiciones y métodos para la predicción de la sensibilidad y de la resistencia a fármacos, y de la progresión de una enfermedad |
WO2011146568A1 (en) * | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
CN107266435A (zh) * | 2010-11-23 | 2017-10-20 | Abbvie 公司 | 细胞凋亡诱导剂的盐和晶形 |
BR112013028890A2 (pt) | 2011-05-09 | 2017-01-31 | Univ Virginia Patent Foundation | composições e métodos para o tratamento de câncer |
WO2013182668A1 (en) * | 2012-06-08 | 2013-12-12 | F. Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
CN111481552A (zh) * | 2012-09-07 | 2020-08-04 | 吉宁特有限公司 | II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗 |
CN104370905B (zh) * | 2014-10-22 | 2016-06-01 | 南京友杰医药科技有限公司 | Bcl-2抑制剂ABT-199的合成 |
-
2016
- 2016-07-06 SI SI201630278T patent/SI3319995T1/sl unknown
- 2016-07-06 BR BR112017028012A patent/BR112017028012A2/pt active Search and Examination
- 2016-07-06 CN CN202110774906.9A patent/CN113607945A/zh active Pending
- 2016-07-06 DK DK16741212.1T patent/DK3319995T3/da active
- 2016-07-06 JP JP2018500373A patent/JP6910339B2/ja active Active
- 2016-07-06 EP EP16741212.1A patent/EP3319995B1/en active Active
- 2016-07-06 MX MX2018000135A patent/MX2018000135A/es unknown
- 2016-07-06 AU AU2016290065A patent/AU2016290065B2/en active Active
- 2016-07-06 HU HUE16741212A patent/HUE044139T2/hu unknown
- 2016-07-06 CA CA2990465A patent/CA2990465A1/en active Pending
- 2016-07-06 WO PCT/US2016/041184 patent/WO2017007846A1/en active Application Filing
- 2016-07-06 PL PL16741212T patent/PL3319995T3/pl unknown
- 2016-07-06 CN CN201680040184.1A patent/CN107922504B/zh active Active
- 2016-07-06 KR KR1020187000356A patent/KR20180021060A/ko active IP Right Grant
- 2016-07-06 RS RS20190727A patent/RS58823B1/sr unknown
- 2016-07-06 LT LTEP16741212.1T patent/LT3319995T/lt unknown
- 2016-07-06 PT PT16741212T patent/PT3319995T/pt unknown
- 2016-07-06 ES ES16741212T patent/ES2731377T3/es active Active
- 2016-07-06 TR TR2019/08138T patent/TR201908138T4/tr unknown
-
2017
- 2017-12-20 IL IL256451A patent/IL256451B/en unknown
- 2017-12-20 US US15/849,018 patent/US10898570B2/en active Active
-
2019
- 2019-06-05 HR HRP20191019TT patent/HRP20191019T1/hr unknown
-
2020
- 2020-12-21 US US17/129,096 patent/US20210213130A1/en not_active Abandoned
-
2021
- 2021-07-06 JP JP2021112329A patent/JP2021178825A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
LT3319995T (lt) | 2019-07-10 |
CN107922504A (zh) | 2018-04-17 |
US20180140700A1 (en) | 2018-05-24 |
JP2021178825A (ja) | 2021-11-18 |
HUE044139T2 (hu) | 2019-09-30 |
CN113607945A (zh) | 2021-11-05 |
DK3319995T3 (da) | 2019-06-24 |
CA2990465A1 (en) | 2017-01-12 |
MX2018000135A (es) | 2018-03-23 |
EP3319995A1 (en) | 2018-05-16 |
US20210213130A1 (en) | 2021-07-15 |
TR201908138T4 (tr) | 2019-06-21 |
WO2017007846A1 (en) | 2017-01-12 |
RS58823B1 (sr) | 2019-07-31 |
SI3319995T1 (sl) | 2019-07-31 |
PT3319995T (pt) | 2019-06-14 |
JP6910339B2 (ja) | 2021-07-28 |
AU2016290065B2 (en) | 2022-08-11 |
KR20180021060A (ko) | 2018-02-28 |
AU2016290065A1 (en) | 2018-01-18 |
JP2018521064A (ja) | 2018-08-02 |
EP3319995B1 (en) | 2019-04-17 |
ES2731377T3 (es) | 2019-11-15 |
IL256451B (en) | 2021-12-01 |
US10898570B2 (en) | 2021-01-26 |
HRP20191019T1 (hr) | 2019-09-06 |
IL256451A (en) | 2018-02-28 |
CN107922504B (zh) | 2021-07-30 |
BR112017028012A2 (pt) | 2018-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL290959A (en) | Preparations containing antibody-drug conjugates and methods for their production | |
IL268102A (en) | Anti-GPR 20 antibody and anti-GPR 20 antibody-drug conjugate | |
IL253712B (en) | Mysterlein derivatives for coupling and healing | |
HK1231367A1 (zh) | 抗體藥物偶聯物、試劑和製備方法及其治療用途 | |
IL248961A0 (en) | Oristatin histories and their conjugations | |
ZA201905727B (en) | Combination therapy with an anti-axl antibody-drug conjugate | |
HUE049291T2 (hu) | Antitest-hatóanyag konjugátumok és immuntoxinok | |
IL269945B (en) | Conjugates of pyrrolobenzodiazepine | |
HUE040517T2 (hu) | Antitest-hatóanyag konjugátumok és immuntoxinok | |
IL272625A (en) | Conjugates of pyrrolobenzodiazepine | |
IL266369A (en) | Combination treatment with antibody-drug conjugates and parp inhibitors | |
PT3544637T (pt) | Conjugados omv-antigénio nativos e sua utilização | |
IL256451A (en) | Combined treatment with anti-her2 antibody coupling - drug and bcl-2 inhibitor | |
GB201818562D0 (en) | Pyrrolobenzodiazephones and conjugates thereof | |
GB201712101D0 (en) | nOMV-ANTIGEN CONJUGATES AND USE THEREOF | |
GB201721337D0 (en) | Pyrrolobenzodiazepine conjugates | |
GB201706133D0 (en) | Pyrrolobenzodiazepine conjugates |